SEC Form 4 · accession 0001209191-17-044944
IMMUNE DESIGN CORP. · IMDZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lewis W Coleman
Director
Period of report
Jul 10, 2017
Accepted (ET)
Jul 12, 2017 · 6:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001437786
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 10, 2017 | P | 10,000 | $8.995 | A | 18,000 | I | By Trust |
| Common StockF2 | Jul 11, 2017 | P | 2,000 | $9.325 | A | 20,000 | I | By Trust |
| Common Stock | holding | — | — | — | 3,000 | I | By Wife's IRA | |
| Common Stock | holding | — | — | — | 40,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported price in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $8.85 to $9.20 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.
- F2The reported price in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $9.30 to $9.35 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.